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Abstract 
 
Weight loss inhibits thyrotropic function and reduces metabolic rate, thereby contributing to 
weight regain. Under negative energy balance there is an increase in the hypothalamic 
expression of both neuropeptide Y (NPY) and agouti related peptide (AgRP), the endogenous 
antagonist of melanocortin 4 (MC4) receptors. Both NPY and MC4 receptor antagonism 
reduce thyrotropic function centrally, but it is not known whether these pathways operate by 
similar or distinct mechanisms. We compared the time-course of effects of acute or chronic 
intracerebroventricular (ICV) administration of NPY (1.2 nmol acute bolus, or 3.5 nmol/day for 
6 days) or the MC4 receptor antagonist HS014 (1.5 nmol bolus, or 4.8 nmol/day) on plasma 
concentrations of thyroid stimulating hormone (TSH) or free thyroxine (T4) in male rats pair-
fed with vehicle-infused controls. These doses equipotently induced hyperphagia in acute 
studies, reduced latency to feed, and increased white adipose tissue mass after 6 days of 
infusion. Acute central NPY but not HS014 administration significantly reduced plasma TSH 
concentrations within 30–60 min and plasma free T4 levels within 90–120 min. These 
inhibitory effects were sustained for up to 5–6 days of continuous NPY infusion. HS014 
induced a transient decrease in plasma free T4 levels that was observed only after 1–2 days 
of continuous ICV infusion. While both NPY and HS014 significantly increased 
corticosteronemia within an hour after ICV injection, the effect of NPY was significantly more 
pronounced and was sustained for up to 4 days of administration. Both NPY and HS014 
significantly decreased the brown adipose tissue protein levels of uncoupling protein-3. We 
conclude that central NPY and MC4 antagonism decrease thyrotropic function via partially 
distinct mechanisms with different time courses, possibly involving glucocorticoid effects of 
NPY. MC4 receptor antagonism increases adiposity via pathways independent of increased 
food intake or changes in circulating concentrations of TSH, free T4 or corticosterone. 
1. Introduction 	  
A major challenge for the treatment of obesity is that loss of just 5–10% of body weight leads 
to metabolic changes that inhibit further weight loss. Overweight or obese people who lost 
weight by moderate or severe energy restriction (with or without physical activity) showed 
significant decreases in circulating concentrations of the most active thyroid hormone free 
triiodothyronine (T3) and/or a significant increase in that of the inactive hormone, reverse T3, 
as well as significant reductions in circulating concentrations of thyroid stimulating hormone 
(TSH) and free thyroxine (T4), the precursor to T3 (Hukshorn et al., 2003a, Hukshorn et al., 
2003b, Rosenbaum et al., 2000, Weinsier et al., 2000, Wadden et al., 1990, Naslund et al., 
2000 and Douyon and Schteingart, 2002). As thyroid hormones are major regulators of 
energy expenditure, acting on peripheral tissues to directly influence cellular metabolism 
(Silva, 2003) as well as on hypothalamic sites to regulate AMP-activated protein kinase, fatty 
acid metabolism and subsequent sympathetic nervous output (Lopez et al., 2010), reduced 
thyroid function likely contributes to the concomitant reduction in metabolic rate or energy 
expenditure (Weinsier et al., 2000, Rosenbaum et al., 1997, Leibel et al., 1995, Westerterp-
Plantenga et al., 2001, Westerterp-Plantenga et al., 2004, Hukshorn et al., 2003a, Hukshorn 
et al., 2003b, Menozzi et al., 2000, Martin et al., 2007 and Sainsbury and Zhang, 2010). The 
weight loss-induced drop in energy expenditure is a significant predictor of weight regain 
(Pasman et al., 1999 and Goran, 2000), so insights into mechanisms for decreased thyroid 
function and energy expenditure could lead to improved weight loss interventions. 
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 The decreases in thyroid function and metabolic rate that occur during negative 
energy balance are likely to be mediated, at least in part, by the action of neuropeptide Y 
(NPY) and melanocortin receptors in the hypothalamus (Lechan and Fekete, 2006). NPY is 
an orexigenic peptide (Stanley et al., 1985 and Clark et al., 1984) synthesized by neurons 
within the arcuate nucleus of the hypothalamus (Bai et al., 1985). These NPY-ergic neurons 
also synthesize another orexigenic agent, agouti related peptide (AgRP) (Ollmann et al., 
1997), which antagonizes melanocortin 3 (MC3) and melanocortin 4 (MC4) receptors 
expressed in the brain (Ollmann et al., 1997). The NPY–AgRP synthesizing neurons in the 
arcuate nucleus are distinct from the cells that express proopiomelanocortin (Elias et al., 
1998), the pre-cursor for the anorexic alpha-melanocyte stimulating hormone (α-MSH), which 
acts as an agonist on brain MC3 and MC4 receptors (Mountjoy et al., 1992 and Adan et al., 
1994). NPY–AgRP and POMC-expressing neurons in the arcuate nucleus project to the 
paraventricular nucleus (PVN) (Baker and Herkenham, 1995 and O’Donohue et al., 1979), 
where they exert stimulatory (NPY and AgRP) (Stanley et al., 1985 and Clark et al., 1984) or 
inhibitory (α-MSH) (Thiele et al., 1998 and Brown et al., 1998) effects on food intake. During 
energy restriction in rodents, the protein or mRNA levels of NPY and AgRP are increased in 
the hypothalamus whereas the mRNA expression of proopiomelanocortin is reduced 
(Sainsbury and Zhang, 2010). This change likely has important effects on the hypothalamo-
pituitary thyroid axis, as NPY, AgRP, and α-MSH-containing neuronal endings have been 
detected in close association with neurons in the PVN that synthesize thyrotropin-releasing 
hormone (TRH) in rodents (Legradi and Lechan, 1999) and in humans (Mihaly et al., 2000). 
Moreover, TRH-expressing neurons in the PVN of the mouse are known to express Y1 
receptor-like immunoreactivity (Broberger et al., 1999). Unlike the MC3 receptor, MC4 
receptor mRNA (Mountjoy et al., 1994) as well as Y1 and Y5 receptor immunoreactivity 
(Wolak et al., 2003) are found in both parvicellular and magnocellular neurons of the PVN as 
recently reviewed (Lechan and Fekete, 2006), suggesting direct effects of NPY and 
melanocortins on the thyrotropic axis at the level of the hypothalamus. Indeed, central 
administration of NPY, Y1 or Y5 receptor agonists, AgRP or MC4 receptor antagonists to 
normal rodents significantly reduces function of the thyrotropic axis, indicated by reductions in 
expression of TRH in the PVN, and a decrease in circulating concentrations of TSH and T3 or 
T4 (Fekete et al., 2001, Fekete et al., 2002a, Fekete et al., 2002b, Small et al., 2001 and Kim 
et al., 2000). MC4 receptors are critical for the inhibitory effects of AgRP on thyroid function, 
as the effects were not seen in MC4 receptor knockout mice (Fekete et al., 2004). 
Conversely, central injection of MC3 or MC4 receptor agonists such as α-MSH or a stable 
analog of α-MSH increased circulating TSH (Kim et al., 2000) or free T4 concentrations 
(Fekete et al., 2000) in fasting rodents, probably via direct actions which stimulate TRH 
expression and release in the PVN (Kim et al., 2000 and Fekete et al., 2000). Further 
evidence for a physiological role of MC4 in the regulation of thyroid function is the recent in 
vivo discovery that thyroid hormones inhibit MC4 receptor expression in brain nuclei known to 
regulate thyroid function or energy homeostasis, namely the PVN, arcuate nucleus of the 
hypothalamus and brain stem, via their receptor interactions with thyroid hormone-response 
elements on the MC4 receptor gene ( Decherf et al., 2010). This negative feedback loop, 
whereby MC4 receptor activation stimulates thyroid hormone release which in turn down-
regulates MC4 receptor expression, would serve to limit the catabolic effects of MC4 receptor 
agonism (Decherf et al., 2010). Taken together, these collective findings suggest that 
alterations in endogenous NPY and melanocortin tonus could contribute to the decreased 
thyroid function (and subsequently reduced energy expenditure) that have been consistently 
observed during conditions of negative energy balance, such as during weight loss in obese 
individuals. 
 NPY, AgRP and their receptors share not only overlapping distribution patterns, but 
also overlapping functions. While such functional redundancy could contribute to species 
survival during prolonged period of food restriction, it poses a particular challenge for 
voluntary weight loss strategies. Indeed, recent clinical trials in humans of MK-0493, an MC4 
receptor agonist, revealed a slight but significant decrease in food intake and a modest 
decrease in body weight from baseline, with no significant effect on body weight after 12–
18 weeks (Krishna et al., 2009). In light of the redundancies in systems that regulate energy 
homeostasis or thyroid function, we aimed to investigate the mechanisms by which NPY and 
AgRP may inhibit activity of the hypothalamo-pituitary–thyrotropic axis, and to determine 
whether this inhibition is occurring through distinct or overlapping mechanisms. To this end 
we investigated the time course of effects of acute versus chronic intracerebroventricular 
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(ICV) infusion of NPY or the MC4 receptor antagonist, HS014, on thyrotropic function in rats. 
 
2. Materials and methods 
 
2.1. Experimental animals 
All procedures were approved by the Animal Experimentation Ethics Committee of the 
Garvan Institute/St. Vincent’s Hospital and are in keeping with the National Health and 
Medical Research Council of Australia’s guidelines on animal experimentation. Male Wistar 
rats were purchased from Animal Resources Centre (Perth, Australia) at weights of 250–
280 g. They were housed in groups in plastic cages on pellet paper bedding and under 
conditions of controlled temperature (23 °C) and illumination (6:00–18:00 h). They were 
allowed ad libitum access to standard laboratory chow (Norco Stockfeeds, South Lismore, 
Australia) and water, unless otherwise stated. 
 
2.2. Placement of chronic intracerebroventricular (ICV) and jugular cannulae 
Animals were anesthetized with an intraperitoneal injection of ketamine/xylazine at 60 and 
10 mg/kg, respectively (Mavlab, Brisbane, Australia, and Troy Laboratories, Sydney, 
Australia) for the placement of a cannula in the right lateral cerebral ventricle (Sainsbury et 
al., 1997), which was used for all ICV administrations. Another cannula was placed in the 
right jugular vein for blood sampling. Rats received an intramuscular injection of penicillin at 
0.3 mg/kg (Troy Laboratories, Sydney, Australia) as well as subcutaneous analgesic, 
buprenorphine (Temgesic, 0.025 mg/kg, Reckitt and Coleman, Hull, UK) and were left to 
recover to pre-surgery weights (7–10 days) in individual cages, with daily handling to 
minimize stress. 
 
2.3. Acute ICV injection of NPY and HS014 
A subset of rats were used in acute (2–4 h) studies following bolus ICV injection of porcine 
NPY (1.2 nmol, Auspep, Melbourne, Australia), or the synthetic MC4 receptor antagonist 
HS014 (1.5 nmol, Auspep, Melbourne, Australia) or vehicle (5 mL 0.9% NaCl) for control rats. 
Injections were made over 60 s, and animals were then returned to their cages. Blood 
samples (0.3 mL) were collected from the jugular cannula at 0, 7.5, 15, 30, 60, 90, and 
120 min after ICV injections using sodium citrate (6.1 mg/mL in 0.9% NaCl) as an 
anticoagulant. Food was not available during the sampling period. Plasma was frozen at 
−20 °C until subsequent analysis as described below. 
 
2.4. Chronic ICV infusion of NPY and HS014 
Rats were anesthetized with halothane (Veterinary Companies of Australia, Artarmon, 
Sydney, Australia) for implantation of subcutaneous osmotic minipumps (model 2001, Alza 
Corporation, Palo Alto, CA, US) (Sainsbury et al., 1997) which were connected via 
polyethylene tubing to the ICV cannula for central infusion of porcine NPY (3.5 nmol/day), 
HS014 (4.8 nmol/day), or vehicle (24 µL/day of 0.9% NaCl) for control rats. Food intake of the 
NPY- and HS014-infused rats was restricted to that of vehicle-infused animals (30–32 g/day) 
to ensure that any differences observed were not due to increased food intake. Rats were 
fasted for 2–3 h (from ∼9.30–12.30 h) prior to collection of blood samples (0.3 mL) from the 
jugular cannula between 11:30 and 12:30 h each day using sodium citrate (6.1 mg/mL in 
0.9% NaCl) as an anticoagulant. All plasma samples were frozen and stored at −20 °C until 
analysis. 
 
2.5. Plasma analyses 
Plasma concentrations of glucose were measured using a commercial kit (glucose oxidase 
method, Trace Scientific, Melbourne, Australia). Commercial radioimmunoassay kits were 
used for the determination of plasma insulin, leptin (Linco Research, St. Louis, MO, US), 
corticosterone, free T4, and TSH levels (ICN Biomedicals, Costa Mesa, CA, US), except for 
chronic infusion studies, where plasma TSH concentrations were estimated by 
chemiluminescent immunometric assay (CLIMA) on Immulite® 2000 (DPC Biermann GmbH, 
Friedberg, Germany) and free T4 was estimated by Microparticles Enzyme Immunoassay on 
AxSYM® (Abbott Park Illinois, USA). For measurement of TSH and Free T4 levels, plasma 
was combined from two time points from each rat (i.e. t = 30 and t = 60 min sample; t = 90 
and t = 120 min sample; t = 1 and t = 2 day sample; t = 5 and t = 6 day sample), in order to 
have sufficient plasma volume for the assay. 
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2.6. Tissue analyses 
After 6 days of ICV infusion, rats were anaesthetized with pentobarbitone sodium (Nembutal; 
Abbott laboratories, Sydney, Australia), the interscapular brown adipose tissue (BAT) was 
removed, weighed, rapidly frozen on liquid nitrogen and stored at −80 °C until subsequent 
analysis of UCP3 protein levels as previously described (Molero et al., 2004). The thyroid 
gland was also removed and weighed. The right inguinal and right epididymal white adipose 
tissue depots were removed and weighed, as was the mesenteric white adipose tissue depot. 
 
2.7. Statistics 
Statistics were performed using Statview version 4.5 (Abacus Concepts, CA, US). Repeated 
measures or factorial ANOVA tests were used for the statistical analysis of results, with 
Fisher’s post hoc tests where appropriate. Data are expressed as mean ± SEM (or 
mean ± SD where the graph shows groups with less than six animals), and the results were 
considered statistically significant if P < 0.05. 
 
3. Results 
 
3.1. Acute central NPY but not HS014 injection decreases circulating thyroid hormone 
concentrations and increases insulinemia 
In order to investigate immediate effects of central NPY or MC4R antagonist administration 
on thyroid function, we measured changes in circulating thyroid hormone concentrations in 
response to acute ICV injection of NPY or HS014 in rats that did not have access to food. 
There was no significant difference among the three groups of rats with respect to body 
weight at the time of injection (data not shown). We have shown previously that the acute 
doses of NPY (1.2 nmol) and HS014 (1.5 nmol) chosen for this study were equipotent in that 
both agents produced an equivalent, 10-fold increase in total food intake in the 4 h after ICV 
injection compared to vehicle-injected controls (Baran et al., 2002). Despite comparable 
actions on food intake in rats that were allowed to eat, only NPY injection had effects on 
thyroid function. Acute ICV administration of NPY resulted in a significant reduction in plasma 
concentrations of TSH relative to vehicle-injected controls at 30–60 min post-injection, and 
this effect was sustained at 90–120 min post-injection (Fig. 1A). Acute ICV NPY injection also 
led to a significant reduction in plasma free T4 concentrations compared to vehicle-injected 
control rats at 90–120 min after injection (Fig. 1B). In contrast to these inhibitory effects of 
NPY, there were no effects of acute ICV HS014 injection on the plasma concentrations of 
TSH or Free T4 (Fig. 1). 
 Acute ICV NPY administration is known to modulate circulating concentrations of 
corticosterone and insulin (Sainsbury et al., 1996 and Wisialowski et al., 2000), both of which 
– in addition to thyroid hormones – influence energy homoestasis. Moreover, corticosterone 
and insulin status can have significant effects on thyroid hormone concentrations (Kakucska 
et al., 1995, Alkemade et al., 2005, Nicoloff et al., 1970, Gonzalez et al., 1980 and Mitsuma 
and Nogimori, 1982). Therefore, in order to determine whether changes in insulin or 
corticosterone levels may have contributed to these changes in thyroid hormone 
concentrations, we investigated circulating insulin and corticosterone concentrations in NPY- 
and HS014-injected rats. Both peptides induced a significant increase in plasma 
corticosterone levels relative to vehicle-injected control rats within the first 120 min of 
injection, and this effect was significantly more pronounced in NPY- than in HS014-injected 
rats (Fig. 2A). While acute ICV injection of neither NPY nor HS014 had any significant effect 
on glycemia (Fig. 2B), acute central NPY but not HS014 administration significantly increased 
insulinemia within the 2 h after injection (Fig. 2C). 
 
3.2. Chronic ICV NPY or HS014 administration both stimulate appetite and induce obesity 
As acute ICV HS014 administration did not influence circulating thyroid hormone 
concentrations, we sought to determine whether longer-term central administration (up to 
6 days) would have effects on the thyrotropic axis. In these chronic studies, all animals were 
pair fed the same amount as vehicle-infused controls in order to eliminate effects of NPY- or 
HS014-induced hyperphagia on endocrine parameters. Therefore, latency to feed was 
measured as an index of biological potency of the selected doses of NPY and HS014. In all of 
the NPY- and HS014-infused rats, latency to feed was less than 30 s on each of days 2–6 of 
infusion compared with greater than 60 s in vehicle-infused control rats, indicating that both 
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peptides stimulated appetite in all experimental rats. 
 There was no significant difference between vehicle-, NPY-, or HS014-infused rats 
with respect to body weight before or after the 6 days of ICV infusion (Table 1). This is 
consistent with data showing that whereas chronic ICV NPY or MC4 receptor antagonist 
infusion significantly increased body weight in ad libitum-fed rats, no such increase is 
observed when hyperphagia is prevented by pair-feeding with vehicle-infused controls ( 
Baran et al., 2002). 
	  	  	  	  
	  
2.4. Chronic ICV infusion of NPY and HS014
Rats were anesthetized with halothane (Veterinary Companies
of Australia, Artarmon, Sydney, Australia) for implantation of sub-
cutaneous osmotic minipumps (model 2001, Alza Corporation,
Palo Alto, CA, US) (Sainsbury et al., 1997) which were connected
via polyethylene tubing to the ICV cannula for central infusion of
porcine NPY (3.5 nmol/day), HS014 (4.8 nmol/day), or vehicle
(24 lL/day of 0.9% NaCl) for control rats. Food intake of the NPY-
and HS014-infused rats was restricted to that of vehicle-infused
animals (30–32 g/day) to ensure that any differences observed
were not due to increased food intake. Rats were fasted for 2–3 h
(from !9.30–12.30 h) prior to collection of blood samples
(0.3 mL) from the jugular cannula between 11:30 and 12:30 h each
day using sodium citrate (6.1 mg/mL in 0.9% NaCl) as an anticoag-
ulant. All plasma samples were frozen and stored at "20 !C until
analysis.
2.5. Plasma analyses
Plasma concentrations of glucose were measured using a com-
mercial kit (glucose oxidase method, Trace Scientific, Melbourne,
Australia). Commercial radioimmunoassay kits were used for the
determination of plasma insulin, leptin (Linco Research, St. Louis,
MO, US), corticosterone, free T4, and TSH levels (ICN Biomedicals,
Costa Mesa, CA, US), except for chronic infusion studies, where
plasma TSH concentrations were estimated by chemiluminescent
immunometric assay (CLIMA) on Immulite" 2000 (DPC Biermann
GmbH, Friedberg, Germany) and free T4 was estimated by Micro-
particles Enzyme Immunoassay on AxSYM" (Abbott Park Illinois,
USA). For measurement of TSH and Free T4 levels, plasma was
combined from two time points from each rat (i.e. t = 30 and
t = 60 min sample; t = 90 and t = 120 min sample; t = 1 and
t = 2 day sample; t = 5 and t = 6 day sample), in order to have suffi-
cient plasma volume for the assay.
2.6. Tissue analyses
After 6 days of ICV infusion, rats were anaesthetized with pen-
tobarbitone sodium (Nembutal; Abbott laboratories, Sydney, Aus-
tralia), the interscapular brown adipose tissue (BAT) was
removed, weighed, rapidly frozen on liquid nitrogen and stored
at "80 !C until subsequent analysis of UCP3 protein levels as pre-
viously described (Molero et al., 2004). The thyroid gland was also
removed and weighed. The right inguinal and right epididymal
white adipose tissue depots were removed and weighed, as was
the mesenteric white adipose tissue depot.
2.7. Statistics
Statistics were performed using Statview version 4.5 (Abacus
Concepts, CA, US). Repeated measures or factorial ANOVA tests
were used for the statistical analysis of results, with Fisher’s post
hoc tests where appropriate. Data are expressed as mean ± SEM
(or mean ± SD where the graph shows groups with less than six
animals), and the results were considered statistically significant
if P < 0.05.
3. Results
3.1. Acute central NPY but not HS014 injection decreases circulating
thyroid hormone concentrations and increases insulinemia
In order to investigate immediate effects of central NPY or
MC4R antagonist administration on thyroid function, we measured
changes in circulating thyroid hormone concentrations in response
to acute ICV injection of NPY or HS014 in rats that did not have ac-
cess to food. There was no significant difference among the three
groups of rats with respect to body weight at the time of injection
(data not shown). We have shown previously that the acute doses
of NPY (1.2 nmol) and HS014 (1.5 nmol) chosen for this study were
equipotent in that both agents produced an equivalent, 10-fold in-
crease in total food intake in the 4 h after ICV injection compared
to vehicle-injected controls (Baran et al., 2002). Despite compara-
ble actions on food intake in rats that were allowed to eat, only
NPY injection had effects on thyroid function. Acute ICV adminis-
tration of NPY resulted in a significant reduction in plasma concen-
trations of TSH relative to vehicle-injected controls at 30–60 min
post-injection, and this effect was sustained at 90–120 min post-
injection (Fig. 1A). Acute ICV NPY injection also led to a significant
reduction in plasma free T4 concentrations compared to vehicle-
injected control rats at 90–120 min after injection (Fig. 1B). In con-
trast to these inhibitory effects of NPY, there were no effects of
acute ICV HS014 injection on the plasma concentrations of TSH
or Free T4 (Fig. 1).
Acute ICV NPY administration is known to modulate circulating
concentrations of corticosterone and insulin (Sainsbury et al.,
1996; Wisialowski et al., 2000), both of which – in addition to thy-
roid hormones – influence energy homoestasis. Moreover, cortico-
sterone and insulin status can have significant effects on thyroid
hormone concentrations (Kakucska et al., 1995; Alkemade et al.,
2005; Nicoloff et al., 1970; Gonzalez et al., 1980; Mitsuma and
N gimori, 1982). Therefore, in order to determine whether changes
in insulin or corticosterone levels may have contributed to these
changes in thyroid hormone concentrations, we investigated circu-
lating insulin and corticosterone conce trations in NPY- an
Fig. 1. Acute central administration of NPY but not the melanocortin 4 receptor
antagonist HS014 reduces circulating thyroid hormone concentrations. Plasma
concentrations of (A) thyroid stimulating hormone (TSH) and (B) free thyroxine
(free T4) at various times after acute intracerebroventricular injection of NPY
(1.2 nmol) or HS014 (1.5 nmol) compared with vehicle injected control rats (5.0 lL
of 0.9% NaCl). Plotted values are means ± SEM of 8–10 rats per group. ⁄P < 0.05 or
⁄⁄P < 0.01 versus vehicle-injected control rats at the same time point, or the
comparison shown by horizontal bars.
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uncoupling protein 3 (UCP-3) in this tissue was determined, since
the expression and activity of UCP-3 is known to be regulated by
thyroid function (Lanni et al., 2003; Flandin et al., 2009). The
weight of brown adipose tissue depots were significantly increased
in both NPY- and HS014-infused rats relative to controls (Table 1).
As shown in Fig. 5, brown adipose tissue UCP-3 protein levels were
significantly decreased in both NPY- and HS014-infused rats rela-
tive to vehicle-infused controls after 6 days of ICV administration.
Previous work from our group and others has shown that 3–7 days
central NPY, HS014 or AgRP infusion in rats also results in signifi-
cant decreases in the mRNA expression of brown adipose tissue
UCP-1 (Baran et al., 2002; Fekete et al., 2002a,b), another protein
that is regulated by thyroid function. Taken together, these data
do not suggest that NPY and HS014 have differential effects on
overall thyroid function within brown adipose tissue.
4. Discussion
This data shows that NPY and MC4 receptor antagonism in the
central nervous system inhibit activity of the thyrotropic axis via at
least partially divergent mechanisms with markedly different
time-courses of action. Whereas the effect of ICV NPY to reduce
plasma TSH and free T4 levels is rapid in onset (within 30 min)
and sustained for at least 5–6 days of continuous ICV infusion,
the effect of central MC4 receptor antagonism is slower in onset
and more transient, being apparent only after 1–2 days of ICV
HS014 infusion. Additionally, whereas acute or chronic ICV NPY
administration induced pronounced hypercorticosteronemia and
hyperinsulinemia, HS014 induced a modest rise in corticosteron-
emia only during the first hour after acute ICV injection. As gluco-
corticoids inhibit activity of the thyrotropic axis (Kakucska et al.,
1995; Alkemade et al., 2005; Nicoloff et al., 1970), this finding
may contribute to the observed differences in effects of NPY versus
HS014 on plasma TSH and free T4 concentrations. Despite these
patent dissimilarities in hormonal responses to central administra-
tion of NPY or the MC4 receptor antagonist HS014, both peptides
resulted in marked and significant increases in adiposity and lep-
tinemia after chronic infusion, even though pair feeding with vehi-
cle-infused control animals prevented NPY- and HS014-induced
hyperphagia. Additionally, both peptides inhibited protein levels
of UCP-3 in brown adipose tissue after chronic central infusion,
suggesting equipotent down-regulation of thyroid function, sym-
pathetic activity, or both, in this tissue. Taken together, these find-
ings suggest that; NPY and MC4 receptor antagonism inhibit
thyroid function via different mechanisms; elevations in hypotha-
lamic NPY expression play a stronger role in repressing circulating
thyroid hormone concentrations compared to central MC4 recep-
tor antagonism; MC4 receptor antagonism can increase adiposity
via mechanisms that are independent of hyperphagia and long-
term inhibition of the thyrotropic axis.
Previous studies have shown that 3 days of ICV injection or con-
tinuous infusion of the MC3/MC4 receptor antagonist AgRP into ad
libitum-fed Sprague Dawley rats or mice suppresses circulating
levels of T3 and T4 as well as hypothalamic pro-TRH mRNA in
the PVN with no significant changes in circulating TSH levels
(Fekete et al., 2002a,b; Fekete et al., 2004), consistent with our
data of a significant reduction in plasma free T4 but not TSH
concentrations after 1–2 days of continuous ICV infusion of the
MC4 receptor antagonist HS014. The current findings in pair fed
rats extend these studies to show that the effect of MC4 receptor
antagonism to reduce thyroid hormone levels is not dependent
upon hyperphagia. Moreover, we have shown that the effect of
MC4 receptor antagonism on thyroid hormone levels does not
persist with longer infusion times (5–6 days). This is in keeping
with the observation that people with early onset obesity and
mutations in the MC4 receptor gene exhibit circulating free T4
levels within the normal range, with less than ten percent of these
individuals showing only slight perturbations in circulating TSH
levels (Farooqi et al., 2003). However, one study showed that
seven daily ICV injections of AgRP into ad libitum- or pair fed
Wistar rats significantly decreased plasma TSH concentrations.
This discrepancy could be due to a possible contribution of MC3
receptors to longer-term effects of AgRP on the thyrotropic axis,
since MC3 and MC4 receptors have differential effects on TRH
release from hypothalamic explants in vitro (Kim et al., 2002). In
contrast to unsustained effects of specific MC4 receptor antago-
nism as shown here, it is clear from this study that NPY has a
sustained inhibitory effect on the thyrotropic axis.
The current findings extend previous knowledge of NPY and
melanocortin regulation of thyroid function by demonstrating that
while NPY may be involved in long-term repression of thyroid
function under conditions such as chronic energy restriction, the
shorter-lived MC4 receptor-mediated effect may serve to inhibit
thyroid function only acutely in response to such stimuli. Indeed,
new evidence suggests transience not only of the inhibitory effect
of MC4 receptor antagonism on thyroid function, as shown in the
present study, but also of the stimulatory effect of MC4 receptor
agonism on this axis (e.g. by endogenous a-MSH). In keeping with
this, thyroid hormones inhibit MC4 receptor expression in vivo in
the hypothalamus and brain stem via thyroid hormone receptor
interactions with thyroid hormone-response elements in the
MC4 receptor gene (Decherf et al., 2010). The physiological conse-
quence of this could be that a-MSH/MC4 receptor-mediated in-
creases in thyroid hormone action (as would be expected under
conditions of energy excess) would in turn down-regulate central
MC4 receptors, thereby not only limiting the duration of thyroid
stimulation by a-MSH but also acting to promote positive energy
balance via other effects of MC4 receptor down-regulation, notably
hyperphagia (Decherf et al., 2010). This finding reflects the com-
plexity and redundancy of mechanisms limiting catabolic and pro-
moting anabolic states.
Table 1
Effect of chronic central administration of NPY or the melanocrotin 4 receptor antagonist HS014 on body weight, white adipose tissue mass, thyroid gland weight and brown
adipose tissue mass.
Vehicle NPY HS014
Body weight prior to start of intracerebroventricular infusion (g) 326 ± 3.7 338 ± 11.3 325 ± 3.9
Body weight (g) 323 ± 9 335 ± 10 328 ± 3
Inguinal white adipose tissue weight (% of body weight) 0.41 ± 0.03 0.45 ± 0.06 0.54 ± 0.06*
Epididymal white adipose tissue weight (% of body weight) 0.28 ± 0.02 0.34 ± 0.03 0.41 ± 0.05*
Plasma glucose (mM) 6.4 ± 0.5 6.1 ± 0.3 6.1 ± 0.2
Weight of thyroid gland (% of body weight) 0.19 ± 0.02 0.18 ± 0.01 0.18 ± 0.01
Interscapular brown adipose tissue mass (% of body weight) 0.06 ± 0.01 0.11 ± 0.02* 0.09 ± 0.01*
Unless otherwise stated, measurements were made after 6 days of intracerebroventricular infusion of NPY (3.5 nmol/day), HS014 (4.8 nmol/day) or vehicle for control rats
(24 lL/day of 0.9% NaCl). Data are means ± SEM of 6–8 rats per group.
* P < 0.05 versus vehicle-infused control rats.
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   Investigation of white adipose tissue depot weights after 6 days of ICV infusion showed 
that NPY and HS014 infusion induced similar increases in weight of the mesenteric white 
adipose tissue (WAT) depot (Fig. 3A), as well as similar increases in the combined weight of 
all WAT depots investigated (right inguinal, right epididymal and mesenteric, Fig. 3B). 
Additionally, after 6 days of ICV infusion, both NPY- and HS014-infused rats exhibited 
significant increases in plasma concentrations of leptin (Fig. 3C), in keeping with the 
development of obesity in both groups of animals. Despite similarity of the overall increase in 
adiposity, there was a difference in fat distribution between NPY- and HS014-infused animals; 
only the latter group showed significant increases in relative weight of lower body fat depots, 
with inguinal and epididymal WAT depots being significantly heavier in HS014- but not in 
NPY-infused rats relative to vehicle-infused animals (Table 1). This finding suggests that 
while central NPY infusion particularly enhances mesenteric fat accumulation, MC4 receptor 
antagonism with HS014 promotes fat accumulation in both central and gluteal fat depots. 
 
HS014-injected rats. Both peptides induced a significant increase
in plasma corticosterone levels relative to vehicle-injected control
rats within the first 120 min of injection, and this effect was signif-
icantly more pronounced in NPY- than in HS014-injected rats
(Fig. 2A). While acute ICV injection of neither NPY nor HS014
had any significant effect on glycemia (Fig. 2B), acute central NPY
but not HS014 administration significantly increased insulinemia
within the 2 h after injection (Fig. 2C).
3.2. Chronic ICV NPY or HS014 administration both stimulate appetite
and induce obesity
As acute ICV HS014 administration did not influence circulating
thyroid hormone concentrations, we sought to determine whether
longer-term central administration (up to 6 days) would have ef-
fects on the thyrotropic axis. In these chronic studies, all animals
were pair fed the same amount as vehicle-infused controls in order
to eliminate effects of NPY- or HS014-induced hyperphagia on
endocrine parameters. Therefore, latency to feed was measured
as an index of biological potency of the selected doses of NPY
and HS014. In all of the NPY- and HS014-infused rats, latency to
feed was less than 30 s on each of days 2–6 of infusion compared
with greater than 60 s in vehicle-infused control rats, indicating
that both peptides stimulated appetite in all experimental rats.
There was no significant difference between vehicle-, NPY-, or
HS014-infused rats with respect to body weight before or after
the 6 days of ICV infusion (Table 1). This is consistent with data
showing that whereas chronic ICV NPY or MC4 receptor antagonist
infusion significantly increased body weight in ad libitum-fed rats,
no such increase is observed when hyperphagia is prevented by
pair-feeding with vehicle-infused controls (Baran et al., 2002).
Investigation of white adipose tissue depot weights after 6 days
of ICV infusion showed that NPY and HS014 infusion induced sim-
ilar increases in weight of the mesenteric white adipose tissue
(WAT) depot (Fig. 3A), as well as similar increases in the combined
weight of all WAT depots investigated (right inguinal, right epidid-
ymal and mesenteric, Fig. 3B). Additionally, after 6 days of ICV
infusion, both NPY- and HS014-infused rats exhibited significant
increases in plasma concentrations of leptin (Fig. 3C), in keeping
with the development of obesity in both groups of animals. Despite
similarity of the overall increase in adiposity, there was a differ-
ence in fat distribution between NPY- and HS014-infused animals;
only the latter group showed significant increases in relative
weight of lower body fat depots, with inguinal and epididymal
WAT depots being significantly heavier in HS014- but not in
NPY-infused rats relative to vehicle-infused animals (Table 1). This
finding suggests that while central NPY infusion particularly en-
hances mesenteric fat accumulation, MC4 receptor antagonism
with HS014 promotes fat accumulation in both central and gluteal
fat depots.
3.3. Chronic ICV NPY but not HS014 infusion results in a significant
increase in corticosteronemia and a sustained reduction in circulating
thyroid hormone concentrations
Despite the similar potency of these doses of NPY and HS014 on
appetite and overall fat accumulation, chronic ICV administration
of NPY and HS014 induced differential effects on circulating corti-
costerone concentrations and thyrotropic function. Whereas NPY
induced a significant increase in corticosteronemia relative to vehi-
cle treatment after 4 days of ICV infusion, no such increase in cor-
ticosteronemia was seen in HS014-infused rats (Fig. 3D). Neither
NPY nor HS014 infusion had any significant effect on glycemia
(data not shown). NPY induced significant decreases in plasma
concentrations of TSH and free T4 that were observed at 1–2 days
of ICV infusion and sustained until at least 5–6 days of infusion
(Fig. 4). In contrast, HS014 did not induce any significant effects
on plasma TSH concentrations, albeit there was a 35% reduction
from vehicle-infused control values at 1–2 days after infusion
(Fig. 4A). After 1–2 days of ICV HS014 infusion there was a signif-
icant reduction in plasma free T4 concentrations, but this effect
was normalized in comparison to vehicle-infused control values
by 5–6 days of ICV HS014 infusion (Fig. 4B). This lack of effect of
HS014 on plasma TSH or free T4 concentrations at 5–6 days of
ICV infusion occurred despite the fact that HS014 promoted fat
accumulation at least as efficiently as NPY and continued to stim-
ulate appetite for at least 6 days of ICV infusion. There were no dif-
ferences among groups with respect to the weight of the thyroid
gland at the end of 6 days of ICV infusion (Table 1).
These data suggest that thyroid function in rats is inhibited by
chronic central administration of NPY but not by that of the mela-
nocortin 4 receptor antagonist HS014. It is important to note, how-
ever, that overall thyroid function in individual tissues can alter
even when the circulating concentrations of thyroid hormones
are unchanged, due to local differences in conversion of free T4
to the more active hormone, T3, or to the less active hormone, re-
verse T3, by tissue deiodinase enzymes as reviewed (Bianco et al.,
2002). In order to gain insight into effects of chronic central NPY
versus HS014 infusion on thyroid function in brown adipose tissue,
an important site of energy metabolism, the protein levels of
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Fig. 2. Acute central administration of NPY or the melanocortin 4 receptor
antagonist HS014 stimulates corticosteronemia in rats, but only NPY increases
insulinemia. Plasma concentrations of (A) corticosterone, (B) glucose and (C) insulin
in the 120 min after acute intracerebroventricular injection of NPY (1.2 nmol) or
HS014 (1.5 nmol) compared with vehicle-injected control rats (5.0 lL of 0.9% NaCl).
Plotted values are means ± SEM of 8–10 rats per group. ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001
versus the curve for vehicle-injected controls; DDD P < 0.001 versus the curve for
HS014-injected rats.
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3.3. Chronic ICV NPY but not HS014 infusion results in a significant increase in 
corticosteronemia and a sustained reduction in circulating thyroid hormone concentrations 
Despite the similar potency of these doses of NPY and HS014 on appetite and overall fat 
accumulation, chronic ICV administration of NPY and HS014 induced differential effects on 
circulating corticosterone concentrations and thyrotropic function. Whereas NPY induced a 
significant increase in corticosteronemia relative to vehicle treatment after 4 days of ICV 
infusion, no such increase in corticosteronemia was seen in HS014-infused rats (Fig. 3D). 
Neither NPY nor HS014 infusion had any significant effect on glycemia (data not shown). 
NPY induced significant decreases in plasma concentrations of TSH and free T4 that were 
observed at 1–2 days of ICV infusion and sustained until at least 5–6 days of infusion (Fig. 4). 
NPY and MC4 receptor antagonism have been hypothesized to
influence activity of the thyrotropic axis by reducing cellular cAMP
concentrations leading to reduced phosphorylation of CREB and re-
duced transcription of the TRH gene as recently reviewed (Lechan
and Fekete, 2006). However, the rapidity of the ffect of ICV NPY
infusion on plasma TSH levels (within 30–60 min after acute ICV
injection) suggests that NPY induces at least some of its effects
on plasma TSH levels via mechanisms independent of increased
transcription of the TSH gene. Additionally, while the current data
do not preclude the possibility that NPY and MC4 receptor antag-
onism may reduce plasma free T4 levels via reductions in intracel-
lular cAMP levels and subsequent inhibition of TSH gene
transcription, other mec anism must also be at play to account
for the diff rent time courses of effects.
Fig. 3. Chronic central administration of NPY or the melanocortin 4 receptor
antagonist HS014 increase adiposity and leptinemia in rats, but only NPY increases
corticosteronemia. (A) Mass (as a percent of body weight) of mesenteric white
adipose tissue (WAT) and (B) the summed mass (as a percent of body weight) of
mesenteric, right epididymal and right inguinal WAT depots after 6 days of
intracerebroventricular infusion of NPY (3.5 nmol/day) or HS014 (4.8 nmol/day)
compared with vehicle-infused control rats (24 lL/day of 0.9% NaCl). Plasma
concentrations of (C) leptin and (D) corticosterone after 4 days of intracerebroven-
tricular infusion of NPY or HS014 compared with vehicle-infused controls as
described above. Plotted values are means ± SD of 4–10 rats per group. ⁄P < 0.05,
⁄⁄P < 0.01 or ⁄⁄⁄P < 0.001 versus vehicle-infused control rats or the comparison
shown by horizontal bars.
Fig. 4. Chronic central administration of NPY but not the melanocrotin 4 receptor
antagonist HS014 results in a sustained reduction in circulating thyroid hormone
concentrations. Plasma concentrations of (A) thyroid stimulating hormone (TSH)
and (B) free thyroxine (free T4) after 1–2 or 5–6 days of intracerebroventricular
infusion of NPY (3.5 nmol/day) or HS014 (4.8 nmol/day) compared with vehicle-
infused control rats (24 lL/day of 0.9% NaCl). Plotted values are means ± SD of 4–10
rats per group. ⁄P < 0.05 or ⁄⁄P < 0.01 versus vehicle-infused control rats at the same
time point, or the comparison shown by horizontal bars.
Fig. 5. Chronic central administration of NPY or the melanocortin 4 receptor
antagonist HS014 similarly reduces uncoupling protein 3 (UCP-3) protein levels in
brown adipose tissue. Protein levels of UCP-3 in brown adipose tissue of rats after
6 days of intracerebroventricular infusion of NPY (3.5 nmol/day) or HS014
(4.8 nmol/day), expressed as a percentage of values in vehicle-infused control
animals (24 lL/day of 0.9% NaCl). Plotted values are means ± SD of 4–6 rats per
group. ⁄P < 0.05 versus vehicle-infused control rats.
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In contrast, HS014 did not induce any significant effects on plasma TSH concentrations, 
albeit there was a 35% reduction from vehicle-infused control values at 1–2 days after 
infusion (Fig. 4A). After 1–2 days of ICV HS014 infusion there was a significant reduction in 
plasma free T4 concentrations, but this effect was normalized in comparison to vehicle-
infused control values by 5–6 days of ICV HS014 infusion (Fig. 4B). This lack of effect of 
HS014 on plasma TSH or free T4 concentrations at 5–6 days of ICV infusion occurred 
despite the fact that HS014 promoted fat accumulation at least as efficiently as NPY and 
continued to stimulate appetite for at least 6 days of ICV infusion. There were no differences 
among groups with respect to the weight of the thyroid gland at the end of 6 days of ICV 
infusion (Table 1). 
 These data suggest that thyroid function in rats is inhibited by chronic central 
administration of NPY but not by that of the melanocortin 4 receptor antagonist HS014. It is 
important to note, however, that overall thyroid function in individual tissues can alter even 
when the circulating concentrations of thyroid hormones are unchanged, due to local 
differences in conversion of free T4 to the more active hormone, T3, or to the less active 
hormone, reverse T3, by tissue deiodinase enzymes as reviewed (Bianco et al., 2002). In 
order to gain insight into effects of chronic central NPY versus HS014 infusion on thyroid 
function in brown adipose tissue, an important site of energy metabolism, the protein levels of 
uncoupling protein 3 (UCP-3) in this tissue was determined, since the expression and activity 
of UCP-3 is known to be regulated by thyroid function (Lanni et al., 2003 and Flandin et al., 
2009). The weight of brown adipose tissue depots were significantly increased in both NPY- 
and HS014-infused rats relative to controls (Table 1). As shown in Fig. 5, brown adipose 
tissue UCP-3 protein levels were significantly decreased in both NPY- and HS014-infused 
rats relative to vehicle-infused controls after 6 days of ICV administration. Previous work from 
our group and others has shown that 3–7 days central NPY, HS014 or AgRP infusion in rats 
also results in significant decreases in the mRNA expression of brown adipose tissue UCP-1 
(Baran et al., 2002, Fekete et al., 2002a and Fekete et al., 2002b), another protein that is 
regulated by thyroid function. Taken together, these data do not suggest that NPY and HS014 
have differential effects on overall thyroid function within brown adipose tissue. 
 
4. Discussion 
 
This data shows that NPY and MC4 receptor antagonism in the central nervous system inhibit 
activity of the thyrotropic axis via at least partially divergent mechanisms with markedly 
different time-courses of action. Whereas the effect of ICV NPY to reduce plasma TSH and 
free T4 levels is rapid in onset (within 30 min) and sustained for at least 5–6 days of 
continuous ICV infusion, the effect of central MC4 receptor antagonism is slower in onset and 
more transient, being apparent only after 1–2 days of ICV HS014 infusion. Additionally, 
whereas acute or chronic ICV NPY administration induced pronounced 
hypercorticosteronemia and hyperinsulinemia, HS014 induced a modest rise in 
corticosteronemia only during the first hour after acute ICV injection. As glucocorticoids inhibit 
activity of the thyrotropic axis (Kakucska et al., 1995, Alkemade et al., 2005 and Nicoloff et 
al., 1970), this finding may contribute to the observed differences in effects of NPY versus 
HS014 on plasma TSH and free T4 concentrations. Despite these patent dissimilarities in 
hormonal responses to central administration of NPY or the MC4 receptor antagonist HS014, 
both peptides resulted in marked and significant increases in adiposity and leptinemia after 
chronic infusion, even though pair feeding with vehicle-infused control animals prevented 
NPY- and HS014-induced hyperphagia. Additionally, both peptides inhibited protein levels of 
UCP-3 in brown adipose tissue after chronic central infusion, suggesting equipotent down-
regulation of thyroid function, sympathetic activity, or both, in this tissue. Taken together, 
these findings suggest that; NPY and MC4 receptor antagonism inhibit thyroid function via 
different mechanisms; elevations in hypothalamic NPY expression play a stronger role in 
repressing circulating thyroid hormone concentrations compared to central MC4 receptor 
antagonism; MC4 receptor antagonism can increase adiposity via mechanisms that are 
independent of hyperphagia and long-term inhibition of the thyrotropic axis. 
 Previous studies have shown that 3 days of ICV injection or continuous infusion of 
the MC3/MC4 receptor antagonist AgRP into ad libitum-fed Sprague Dawley rats or mice 
suppresses circulating levels of T3 and T4 as well as hypothalamic pro-TRH mRNA in the 
PVN with no significant changes in circulating TSH levels ( Fekete et al., 2002a, Fekete et al., 
2002b and Fekete et al., 2004), consistent with our data of a significant reduction in plasma 
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free T4 but not TSH concentrations after 1–2 days of continuous ICV infusion of the MC4 
receptor antagonist HS014. The current findings in pair fed rats extend these studies to show 
that the effect of MC4 receptor antagonism to reduce thyroid hormone levels is not dependent 
upon hyperphagia. Moreover, we have shown that the effect of MC4 receptor antagonism on 
thyroid hormone levels does not persist with longer infusion times (5–6 days). This is in 
keeping with the observation that people with early onset obesity and mutations in the MC4 
receptor gene exhibit circulating free T4 levels within the normal range, with less than ten 
percent of these individuals showing only slight perturbations in circulating TSH levels 
(Farooqi et al., 2003). However, one study showed that seven daily ICV injections of AgRP 
into ad libitum- or pair fed Wistar rats significantly decreased plasma TSH concentrations. 
This discrepancy could be due to a possible contribution of MC3 receptors to longer-term 
effects of AgRP on the thyrotropic axis, since MC3 and MC4 receptors have differential 
effects on TRH release from hypothalamic explants in vitro ( Kim et al., 2002). In contrast to 
unsustained effects of specific MC4 receptor antagonism as shown here, it is clear from this 
study that NPY has a sustained inhibitory effect on the thyrotropic axis. 
 The current findings extend previous knowledge of NPY and melanocortin regulation 
of thyroid function by demonstrating that while NPY may be involved in long-term repression 
of thyroid function under conditions such as chronic energy restriction, the shorter-lived MC4 
receptor-mediated effect may serve to inhibit thyroid function only acutely in response to such 
stimuli. Indeed, new evidence suggests transience not only of the inhibitory effect of MC4 
receptor antagonism on thyroid function, as shown in the present study, but also of the 
stimulatory effect of MC4 receptor agonism on this axis (e.g. by endogenous α-MSH). In 
keeping with this, thyroid hormones inhibit MC4 receptor expression in vivo in the 
hypothalamus and brain stem via thyroid hormone receptor interactions with thyroid hormone-
response elements in the MC4 receptor gene ( Decherf et al., 2010). The physiological 
consequence of this could be that α-MSH/MC4 receptor-mediated increases in thyroid 
hormone action (as would be expected under conditions of energy excess) would in turn 
down-regulate central MC4 receptors, thereby not only limiting the duration of thyroid 
stimulation by α-MSH but also acting to promote positive energy balance via other effects of 
MC4 receptor down-regulation, notably hyperphagia (Decherf et al., 2010). This finding 
reflects the complexity and redundancy of mechanisms limiting catabolic and promoting 
anabolic states. 
 NPY and MC4 receptor antagonism have been hypothesized to influence activity of 
the thyrotropic axis by reducing cellular cAMP concentrations leading to reduced 
phosphorylation of CREB and reduced transcription of the TRH gene as recently reviewed 
(Lechan and Fekete, 2006). However, the rapidity of the effect of ICV NPY infusion on plasma 
TSH levels (within 30–60 min after acute ICV injection) suggests that NPY induces at least 
some of its effects on plasma TSH levels via mechanisms independent of increased 
transcription of the TSH gene. Additionally, while the current data do not preclude the 
possibility that NPY and MC4 receptor antagonism may reduce plasma free T4 levels via 
reductions in intracellular cAMP levels and subsequent inhibition of TSH gene transcription, 
other mechanisms must also be at play to account for the different time courses of effects. 
 It is possible that the pronounced and persistent hypercorticosteronemia observed in 
NPY- but not HS014-infused rats contributed to the differential effects on thyroid hormone 
concentrations. Adrenalectomy in rats increases pro-TRH mRNA levels in the PVN, whereas 
administration of exogenous corticosterone or dexamethasone to rats has the opposite effect 
(Kakucska et al., 1995). Similar effects appear to be at play in humans, since people that had 
been treated with glucocorticoids until the time of death showed a significant decrease in TRH 
mRNA levels in the PVN compared to control subjects (Alkemade et al., 2005), and 
glucocorticoid excess suppresses the secretion of TSH in humans (Nicoloff et al., 1970). In 
addition to glucocorticoids, the hypothalamo-pituitary–thyroid axis is regulated by insulin. Rats 
that were made insulin deficient by the administration of streptozotocin showed decreases in 
circulating levels of TSH, T3 and T4 as well as pituitary TSH and hypothalamic TRH content 
(Gonzalez et al., 1980 and Mitsuma and Nogimori, 1982). Thus, it is unlikely that the 
hyperinsulinemia observed after acute (this study) and chronic (Baran et al., 2002) ICV NPY 
but not HS014 administration in pair fed rats could contribute to the differences in effects on 
thyroid hormone concentrations presently observed, in keeping with the observation that 
insulin administration is unable to prevent the fasting-induced reduction in thyrotropic axis in 
rats (Fekete et al., 2006). Taken together, these findings show that acute and chronic ICV 
NPY administration results in significantly more pronounced and more prolonged 
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hypercorticosteronemia than MC4 receptor antagonism with HS014, and this difference could 
contribute to the marked and prolonged inhibition in circulating TSH and free T4 levels that 
are seen in NPY- relative to HS014-infused rats. 
 It is intriguing that chronic central infusion of the MC4 receptor antagonist HS014 in 
rats induced at least as great an increase in white adipose tissue mass as ICV NPY infusion. 
This is despite the fact that the food intake of HS014- and NPY-infused rats was identical, 
being yoked in both cohorts at the level of consumption of vehicle-infused control rats to 
prevent hyperphagia, and infusion of HS014, unlike NPY, did not induce sustained changes in 
circulating levels of TSH, free T4, corticosterone or insulin (Baran et al., 2002) that could have 
contributed to fat accumulation over the 6 days. While these hormonal changes may have 
contributed to the propensity for NPY-infused rats to preferentially deposit excess fat in the 
mesenteric fat depot, they cannot explain the increased overall adiposity of HS014-infused 
animals in the absence of hyperphagia. Alternate obesogenic pathways must be at play. For 
instance, it has been shown that TRH per se can increase body temperature, respiration and 
locomotor activity and stimulate gut functions such as gastric acid secretion, gastro–duodenal 
blood flow, gastric emptying and gastrointestinal motility in the absence of effects on thyroid 
hormone concentrations as recently reviewed ( Lechan and Fekete, 2006). As such, inhibition 
of TRH secretion in HS014-infused rats could conceivably contribute to increased adiposity 
even if circulating thyroid hormone concentrations are unaltered. Additionally, alterations in 
local tissue conversion of T4 to the more active T3 and the less active reverse T3 by 
deiodinase enzymes – which are regulated not only by thyroid hormone concentrations but 
also by sympathetic activity (Bianco et al., 2005) – could also contribute to reduced thyroid 
function and therefore reduced fuel oxidation in tissues even in the absence of changes in 
thyroid hormone levels. In keeping with this, we have shown that both NPY and HS014 
inhibited protein or mRNA levels of brown adipose tissue UCP-3 (this study) and UCP-1 
(Baran et al., 2002), both proteins undergoing major regulation by sympathetic activity and 
thyroid hormones (Lanni et al., 2003). Additionally, NPY and MC4 receptor antagonism are 
known to reduce sympathetic output (Bray, 2000), and this is another mechanism via which 
both NPY and HS014 can alter adiposity independently of changes in food intake or hormonal 
milieu. Unfortunately it was not possible to measure energy expenditure via indirect 
calorimetry in this study, which would have facilitated understanding of how chronic central 
MC4 receptor antagonism increases adiposity in rats despite no difference in energy intake or 
the circulating concentrations of the hormones under study. 
 Taken together, these data exemplify the concept that there are multiple distinct 
mechanisms by which the increases in hypothalamic NPY and AgRP expression that occur 
during negative energy balance can collectively hinder further weight loss and promote fat 
accumulation. The increase in central NPY-ergic activity observed during negative energy 
balance probably contributes more to the associated ongoing decrease in thyrotropic function 
than increases in central MC4 receptor antagonism. Anti-obesity drugs will undoubtedly need 
to target multiple systems in order to facilitate effective and continued weight loss during 
weight loss interventions. 
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